What Is IWO? iShares Russell 2000 Growth ETF

Growth indices sort companies on measures such as sales growth and forecast earnings growth. Applied to large companies, that mostly selects software and semiconductors. Applied to the Russell 2000, it selects a great many biotechnology firms, because a company with a drug in trials and no revenue at all can screen as high growth on forward expectations while its actual income statement shows losses. Healthcare at 29% of the fund is that mechanism working exactly as written.

This changes what drives the fund. A basket weighted toward clinical-stage biotech responds to trial readouts, regulatory decisions and the cost of capital more than it responds to enterprise software spending. Krystal Biotech and BrightSpring Health Services both sit inside the top ten, from different parts of that spectrum. The technology sleeve is present at 22% and includes MaxLinear and JFrog, but it is not the centre of gravity many buyers assume it is.

Industrials at 16% add a third character again. Moog, Argan and ESCO Technologies are aerospace, power infrastructure and engineered products businesses, and they qualify as growth on order books rather than on research pipelines. A single fund therefore blends three quite different return drivers, which is worth knowing before treating it as a pure innovation holding.

Nothing in IWO is larger than 0.7%, and the top ten together are 6.1% of the fund. That is close to the opposite of a large-cap index, where a handful of names can dominate. The practical consequence is that no individual holding can move the fund meaningfully. A biotech that doubles on trial results contributes a rounding error to the total, and one that collapses does the same in reverse.

Diversification of that depth is genuinely useful in a corner of the market where single-company failure is common. It also removes any prospect of stock selection helping, since the fund holds essentially everything that qualifies. What you are buying is the behaviour of the small-cap growth cohort as a group, including the persistent drag from the portion of it that never becomes profitable.

The presence of D-Wave Quantum in the top ten illustrates the reach of the screen. Speculative pre-commercial companies enter these indices as soon as they meet the size and style tests, and they exit when their market value falls or their style classification shifts. The fund does not judge them. It owns them at whatever weight the rules produce.

At 0.24% IWO costs several times what the cheapest small-cap index funds charge, and the gap is worth weighing given how much of small-cap returns can be consumed by costs over long holding periods. The 0.42% yield is close to nothing, which follows directly from the mandate: companies that reinvest everything or that have no earnings to distribute do not pay dividends.

The comparison most people should make is not against large-cap growth but against small-cap blend. Funds tracking the S&P SmallCap 600 apply a profitability requirement that removes much of the loss-making cohort IWO deliberately includes, and they typically cost less. Neither approach is superior in the abstract. They express different views about whether unprofitable small companies belong in a portfolio at all.

IWO fits an investor who wants deliberate exposure to that unprofitable, high-expectation cohort and understands that the ride includes long stretches of disappointment. It is the wrong holding for someone who wants small-cap exposure with the quality filter applied, and the wrong holding for anyone who needs income from the position.

Approximate weights as of August 2026. Each ticker links to its individual stock guide in Walnut.

There are three common ways to get IWO exposure. Buy shares (or fractional shares) of IWO directly at any major broker that lists it. Hold it as a core position and layer more concentrated ideas on top. Or build it into a thematic portfolio in Walnut, so IWO sits alongside other holdings that express the same thesis, with target weights you can rebalance toward. IWO trades like a stock during market hours, so you buy it the same way you would any listed share.

New to buying funds? See how to buy an ETF, step by step.

Whether IWO is a good buy depends less on any single call and more on your time horizon and what you already hold: it tracks the Russell 2000 Growth Index, so the real question is whether you want that exposure in your mix and at what weight. We walk through valuation, concentration, and what would have to be true for it to outperform from here in is IWO a buy?

IWO gives you the Russell 2000 Growth Index exposure in one ticker at a 0.24% expense ratio. Most investors use it as a core holding and layer more concentrated thematic portfolios on top.

Whether IWO is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, concentration, and what would have to be true for it to outperform from here in is IWO a buy?

IWO yields 0.42% as of August 2026, paid by passing through the dividends of its underlying holdings. For the payout schedule, history, and how the distributions are taxed, see IWO dividend: yield and schedule.

New to funds like IWO? Start with what an ETF is, then how to buy an ETF, or browse the full guide to ETF investing.